1Other quality system
The assessment, documentation, and/or procedures for considering the resale of returned drugs were inadequate.
Inspection Record
Jamp Pharma Corporation — Health Canada Inspection Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
2Complaint and recall handling
The assessment, recording, follow-up, and/or investigation of complaints and/or other information about potentially defective products was inadequate.
3Equipment and facility
Evaluation of production processes, equipment, and/or materials was inadequate.
4Training and personnel
The training of personnel before new or revised standard operating procedures were implemented was inadequate.
5Complaint and recall handling
The quality control department did not undertake all of the required activities. The written procedures for recalls were inadequate.
6Quality unit oversight
The quality control department did not evaluate the results of the annual product quality review.
About this record
Extracted automatically from the document of the Health Canada inspection on 2025-01-13. The source is available at the link above.
This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.
Translation and classification are automated and may differ in nuance from the source.
